E diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176, 532?55 (2007). two. Barnes, P. J. Stockley, R. A. COPD: current therapeutic interventions and future approaches. Eur Respir J 25, 1084?106 (2005). three. Owen, C. A. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc two, 373?85; discussion 394?75 (2005). four. Tashkin, D. P. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary illness. N Engl J Med 359, 1543?554 (2008). five. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356, 775?89 (2007). 6. Alsaeedi, A., Sin, D. D. McAlister, F. A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic evaluation of randomized placebo-controlled trials. Am J Med 113, 59?5 (2002). 7. Barnes, P. J., Ito, K. Adcock, I. M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363, 731?33 (2004). eight. Mizushima, T. Drug discovery and improvement focusing on existing medicines: drug re-profiling strategy. J Biochem 149, 499?05 (2011). 9. Tanaka, K. et al. Mepenzolate bromide displays effective effects within a mouse model of chronic obstructive pulmonary illness. Nat Commun 4, (2013). 10. Chen, J. Y. Antispasmodic activity of JB-340 (N-methyl-3-piperidyldiphenylglycolate methobromide) with particular reference to its relative selective action on the sphincter of Oddi, colon and urinary bladder with the dog. Arch Int Pharmacodyn Ther 121, 78?4 (1959). 11. Buckley, J. P., De, F. J. Reif, E. C. The comparative antispasmodic activity of Nmethyl-3-piperidyl diphenylglycolate methobromide (JB-340) and atropine sulfate. J Am Pharm Assoc Am Pharm Assoc (Baltim) 46, 592?94 (1957). 12. Long, J. P. Keasling, H. H. The comparative anticholinergic activity of a series of derivatives of 3-hydroxy piperidine. J Am Pharm Assoc Am Pharm Assoc (Baltim) 43, 616?19 (1954). 13. Drummond, G. R., Selemidis, S., Griendling, K. K. Sobey, C. G. Combating oxidative strain in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10, 453?71 (2011). 14. Gosker, H. R. et al. Altered antioxidant status in peripheral skeletal muscle of sufferers with COPD. Respir Med 99, 118?25 (2005). 15. Rahman, I. MacNee, W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12, 256?65 (2012). 16. Prat, M., Gavalda, A., Fonquerna, S. Miralpeix, M. Inhaled muscarinic antagonists for respiratory diseases: a critique of patents and existing developments (2006?010).Buy3-Hydroxy-1-methylazetidine Professional Opin Ther Pat 21, 1543?573 (2011).935455-28-0 Order 17.PMID:23008002 Kuraki, T., Ishibashi, M., Takayama, M., Shiraishi, M. Yoshida, M. A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastaseinduced emphysema in rats. Am J Respir Crit Care Med 166, 496?00 (2002). 18. Tanaka, K. et al. Therapeutic impact of lecithinized superoxide dismutase on pulmonary emphysema. J Pharmacol Exp Ther 338, 810?18 (2011). 19. Tanaka, K., Sato, K., Aoshiba, K., Azuma, A. Mizushima, T. Superiority of PCSOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice. Am J Physiol Lung Cell Mol Physiol 302, L1250?261 (2012). 20. Bergogne-Berezin, E. Bryskier, A. The suppository kind of antibiotic administration: pharmacokineti.